Brief: Peptron's Pt105 Established Bioequivalence With Takeda's Leuplin
28/11/2022 14:05
Nov 28 (Reuters) - Peptron Inc 087010.KQ :
* PEPTRON'S PT105 ESTABLISHED BIOEQUIVALENCE WITH TAKEDA'S
LEUPLIN
* PEPTRON INC - GLOBAL AND REGIONAL DEAL TO BE INITIATED
* PEPTRON INC - DEVELOPMENT OF 3- AND 6-MONTH GENERIC
LEUPROLIDE
FOR GLOBAL MARKET SOON TO BE INITIATED
Source text for Eikon: ID:nPn5KQQNJa
Further company coverage: 087010.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Peptron
See all newsBrief: Peptron To Divest 24 Billion Won Worth Of Own Shares
Brief: Peptron To Invest 65 Billion Won In New Factory
Brief: Peptron To Conduct Capital Increase Of 120 Billion Won
Australia's Invex Therapeutics drops on ending contract with Peptron
Brief: Peptron's Pt105 Established Bioequivalence With Takeda's Leuplin